Halozyme Therapeutics, Inc.
HALO
$107.39
-$0.92-0.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.78% | -28.13% | -28.64% | 51.73% | 65.22% |
| Total Depreciation and Amortization | 40.47% | 24.25% | 8.29% | 0.24% | -0.10% |
| Total Amortization of Deferred Charges | 12.52% | 7.32% | 2.12% | 0.90% | 0.90% |
| Total Other Non-Cash Items | 2,791.17% | 1,130.52% | 999.72% | -29.74% | -75.11% |
| Change in Net Operating Assets | -21.53% | -79.88% | -70.54% | 16.54% | -74.79% |
| Cash from Operations | 49.44% | 34.45% | 36.01% | 51.63% | 30.43% |
| Capital Expenditure | -74.68% | -20.49% | 34.84% | 16.06% | 39.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 196.60% | 205.48% | 174.25% | 180.64% | 33.32% |
| Cash from Investing | -321.70% | -69.44% | -107.75% | 175.03% | 33.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.18% | -30.98% | -30.98% | -30.09% | 46.26% |
| Repurchase of Common Stock | 32.86% | -34.48% | -36.68% | -134.33% | -118.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 79.11% | 62.35% | 61.08% | -156.83% | -123.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 181.05% | 1,059.57% | 916.31% | 321.29% | -278.38% |